ImmunityBio Secures Exclusive Rights to Develop, Commercialize Tokyo-172 BCG in US
MT Newswires Live
May 18
ImmunityBio (IBRX) signed an exclusive development and supply agreement with Japan BCG Laboratory, or JBL, to get exclusive rights to develop, import, and commercialize the latter's intravesical Tokyo-172 BCG in the US, according to a Saturday statement.
Tokyo-172 BCG is backed by results of a phase 3 study in BCG-naive high-grade non-muscle invasive bladder cancer, which demonstrated Tokyo-172 BCG's non-inferiority to TICE BCG, ImmunityBio said. Tokyo-172 BCG is approved in Japan for this indication, the company added.
ImmunityBio plans to engage with the US Food and Drug Administration to pursue approval in the US, the company said. No financial terms were disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.